The National Association of Community Health Centers this week strongly urged drug manufacturer Merck to eliminate “all conditions imposed on health centers to receive 340B price drugs at contract pharmacies.”
Merck’s April 28 decision to extend its restrictions on 340B pricing involving contract pharmacies to health centers “threatens health centers’ ability to provide affordable, comprehensive primary care and medications to the most vulnerable patients and underserved communities,” NACHC Interim President and CEO Rachel Gonzales-Hanson said in a June 14 letter to Merck President and CEO Robert Davis. The restrictions previously applied to hospital covered entities only.
The National Association of Community Health Centers this week strongly urged drug manufacturer Merck to eliminate “all conditions imposed on health centers to receive 340B price drugs at contract pharmacies.”
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
